Metrics
Publication
235
Open Access
13
UN Sustainable Development Goals
Education
2016 - 2019
2016 - 2019Post Doctorate of Medicine
Trakya University, Turkey
2011 - 2015
2011 - 2015Expertise In Medicine
Istanbul Medeniyet University, Turkey
2003 - 2010
2003 - 2010Undergraduate
Marmara University, School Of Medicine, Turkey
Dissertations
2015
2015Expertise In Medicine
Ailevi akdeniz ateşine ikincil gelişen amiloidozda kardiyovasküler bulguların değerlendirilmesi
Diğer (Kurumlar,hastaneler Vb.)
Research Areas
Avesis Research Areas:
Medicine, Oncology, Health Sciences
WoS Research Areas:
Clinical Medicine (Med)
Research Areas Based on Academic Activities
Avesis Research Areas
WoS Research Areas
Scopus Research Areas
Academic Positions
2021 - Present
2021 - PresentAssociate Professor
Marmara University, School Of Medicine, Internal Medical Sciences
Managerial Experience
2022 - 2024
2022 - 2024Member of the Faculty Board
Marmara University, School Of Medicine, Internal Medical Sciences
Non Academic Experience
2019 - 2021
2019 - 2021Tıbbi Onkoloji Uzmanı-Edirne Sultan I. Murat Devlet Hastanesi
SAĞLIK BAKANLIĞI, Tıbbi Onkoloji Uzmanı-Edirne Sultan I. Murat Devlet Hastanesi
2015 - 2016
2015 - 2016İÇ HASTALIKLARI UZMANI
İSTANBUL GÖZTEPE EĞİTİM VE ARAŞTIRMA HASTANESİ, İÇ HASTALIKLARI UZMANI
2010 - 2011
2010 - 2011PENDİK 3. NOLU İSTASYON BİRİMİ
İSTANBUL İL AMBULANS SERVİSİ BAŞHAKEMLİĞİ (ANADOLU), PENDİK 3. NOLU İSTASYON BİRİMİ
Articles
All (194)
SCI-E, SSCI, AHCI (131)
SCI-E, SSCI, AHCI, ESCI (161)
ESCI (23)
Scopus (156)
TRDizin (49)
Other Publications (8)
2026
20261. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study
SÜTCÜOĞLU O., AKDOĞAN O., Onur İ. D., Çiftçi A., Alkan A., Majidova N., et al.
Discover Oncology
, vol.17, no.1, 2026 (SCI-Expanded, Scopus)
2026
20262. Oncological Perspective on Bone-Metastatic Colorectal Cancer: a Single-Centre Experience
Demi̇rel A., Guren A. K., Inceöz B., Akagunduz F., Kocaaslan E., Agyol Y., et al.
Journal of Gastrointestinal Cancer
, vol.57, no.1, 2026 (ESCI, Scopus)
2026
20263. Development and internal validation of the CLIP-M score for advanced mucosal malignant melanoma: exploratory prognostic stratification and comparative assessment with the RMH score.
Pacaci B., Erkan Ozmarasali B., Deligonul A., Gurbuz A. F., Karakurt Eryilmaz M., Atas Ipek S., et al.
BMC cancer
, 2026 (SCI-Expanded, Scopus)
2026
20264. Comparative overall survival in T4N0 and T2-3N1 non-metastatic colon cancer: a retrospective cohort study.
Akagunduz F., Güren A. K., Kocaaslan E., Paçacı B., Tunç M. A., Demirel A., et al.
Annals of Saudi medicine
, vol.46, no.3, pp.169-177, 2026 (SCI-Expanded, Scopus)
2026
20265. Acquired CD74-ROS1 fusion-mediated osimertinib resistance successfully treated with osimertinib and crizotinib: a case report.
Güren A. K., Kocaaslan E., Ağyol Y., Erel P., Paçacı B., Tunç M. A., et al.
Journal of chemotherapy (Florence, Italy)
, pp.1-5, 2026 (SCI-Expanded, Scopus)
2026
20266. Outcomes of CDK4/6 Inhibitor-Based Therapy in Premenopausal HR+/HER2− Metastatic Breast Cancer: Real World Data From A Multicenter Study
Odabaş H., Alomari O., Orman S., SEVER N., Tuzun E. K., Acarbay A., et al.
Pharmacotherapy
, vol.46, no.4, 2026 (SCI-Expanded, Scopus)
2026
20267. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group.
Yıldız S., Demir H., Özüdoğru T., Günenç D., Gökdere Z. S., Arvas H., et al.
Journal of clinical medicine
, vol.15, no.6, 2026 (SCI-Expanded, Scopus)
2026
20268. Prognostic Impact of Early Metabolic Response on Interim 18F-FDG PET/CT in HR+/HER2− Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
Aliyev V., Güren A. K., Guliyev M., Birsin Z., Günaltılı M., Fidan M. C., et al.
Medicina (Lithuania)
, vol.62, no.3, 2026 (SCI-Expanded, Scopus)
2026
20269. Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR
Bayramgil A., Yücel M. H., Turkoglu E., Guren A. K., Kemik F., Ulufer B., et al.
Journal of Clinical Medicine
, vol.15, no.6, 2026 (SCI-Expanded, Scopus)
2026
202610. Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors.
Gürbüz M., Tural D., Çil T., Demir H., Köstek O., Sever Ö. N., et al.
JCO global oncology
, vol.12, no.3, 2026 (ESCI, Scopus)
2026
202611. Circulating Tumor DNA-Based Assessment of Minimal Residual Disease in Colorectal Cancer: Prognostic and Predictive Implications.
Ozluk A. A., Colley W., Arik Z. B., Kostek O., Sunkari A., Malla M., et al.
Cancers
, vol.18, no.5, 2026 (SCI-Expanded, Scopus)
2026
202612. Second-line nab-paclitaxel and gemcitabine for advanced pancreatic cancer following FOLFIRINOX: outcomes and insights.
Merc Cetınkaya A., Tatlı A. M., Goktas Aydın S., Kılıckap S., Bılıcı A., Bırıcık F. S., et al.
American journal of cancer research
, vol.16, no.1, pp.282-290, 2026 (SCI-Expanded)
2026
202613. Prognostic Value of Treatment-Related Body Composition Changes in Metastatic NSCLC Receiving Nivolumab
KOCAASLAN E., Güren A. K., Akagündüz F., DEMİREL A., TUNÇ M. A., PAÇACI B., et al.
Medicina (Lithuania)
, vol.62, no.1, 2026 (SCI-Expanded, Scopus)
2026
202614. Integration of ımmunotherapy in limited-stage small cell lung cancer: a review of the literature
Güren A. K., DEMİRCAN N. C., SARI M., KÖSTEK O.
Current Medical Research and Opinion
, vol.42, no.1, pp.87-97, 2026 (SCI-Expanded, Scopus)
2026
202615. Capecitabine versus Paclitaxel After CDK4/6 Inhibitor Progression in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study
Birsin Z., Güren A. K., Aliyev V., Guliyev M., Jeral S., Cebeci S., et al.
Breast Cancer: Targets and Therapy
, vol.18, 2026 (SCI-Expanded, Scopus)
2026
202616. Adult-Onset Diffuse Midline Glioma, H3K27-Altered: A Genomics-Guided, Individualized, Multimodal Treatment Approach
Çelebi A., Yıldırım B., Yıldırım E., Işık S., ÇOBAN E., BIYIKLI E., et al.
Brain Sciences
, vol.16, no.1, 2026 (SCI-Expanded, Scopus)
2026
202617. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab.
Güren A. K., Demircan N. C., Gümüşay Ö., Şimşek E. T., Kemik F., Karaoğlu Ç., et al.
Immunotherapy
, vol.18, pp.317-326, 2026 (SCI-Expanded, Scopus)
2026
202618. Prognostic Value of 18F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
KOCAASLAN E., Güren A. K., Akagündüz F., DEMİREL A., TUNÇ M. A., PAÇACI B., et al.
Journal of Clinical Medicine
, vol.15, no.2, 2026 (SCI-Expanded, Scopus)
2026
202619. Prognostic Value of Systemic Immune-Inflammation Index in Mucosal Malignant Melanoma
PAÇACI B., KOCAASLAN E., DEMİREL A., Akagündüz F., TUNÇ M. A., AĞYOL Y., et al.
Journal of Clinical Medicine
, vol.15, no.2, 2026 (SCI-Expanded, Scopus)
2026
202620. Post-CDK4/6 inhibitor treatment landscape in metastatic hormone receptor-positive breast cancer: a narrative review
Güren A. K., Kircali M. F., KÖSTEK O., DEMİRCAN N. C.
Expert Review of Anticancer Therapy
, vol.26, no.4, pp.425-435, 2026 (SCI-Expanded, Scopus)
2026
202621. Trastuzumab Deruxtecan–Induced Interstitial Lung Disease: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Evidence
Güren A. K., DEMİRCAN N. C., SARI M., KÖSTEK O., BAYOĞLU İ. V.
Cancer Control
, vol.33, 2026 (SCI-Expanded, Scopus)
2026
202622. Expression and prognostic importance of lymphocyte activation gene 3 and CD73 in advanced or metastatic hepatocellular carcinoma
Ayhan M., Dogan A., Keser S. H., Başak K., Akdeniz N., Atci M. M., et al.
Journal of International Medical Research
, vol.54, no.1, 2026 (SCI-Expanded, Scopus)
2026
202623. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study
Sahin T. K., Kemik F., Muglu H., Acikgöz Yildiz B., Biter S., Tunbekici S., et al.
Therapeutic Advances in Medical Oncology
, vol.18, 2026 (SCI-Expanded, Scopus)
2025
202524. Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study
Majidova N., Arak H., Ozalp F. R., Bas O., Koker G. O., Ozmarasalı E. B., et al.
Scientific Reports
, vol.15, no.1, 2025 (SCI-Expanded, Scopus)
2025
202525. The Role of Baseline PET/CT Parameters in Predicting Treatment Response in Patients with Locally Advanced Rectal Cancer Undergoing Total Neoadjuvant Therapy
Güren A. K., Başkan Z., Balaban Genç Z. C., Bulun Akyol T., Kocaaslan E., Ağyol Y., et al.
MEDICINA-LITHUANIA
, vol.61, no.8, 2025 (SCI-Expanded, Scopus)
2025
202526. Colorectal Cancer Metastasizing to the Thyroid Gland: A Rare and Interesting Case
Majidova N., Eren Ö. C., Yaşar A., Kircali M. F., Güren A. K., Kocaaslan E., et al.
Journal of Oncological Science
, vol.11, no.2, pp.175-178, 2025 (Scopus, TRDizin)
2025
202527. Clinical and Demographic Features in Malignant Peritoneal Mesothelioma: Treatment Approaches and Factors Affecting Survival
SEVER N., Yildirim S., Gürbüz A. F., Karakaş Kiliç D., Zeynelgil E., Altintaş Y. E., et al.
Journal of Oncological Science
, vol.11, no.2, pp.104-111, 2025 (Scopus, TRDizin)
2025
202528. Clinicopathological features and treatment outcomes of patients with fibrolamellar hepatocellular carcinoma: a retrospective multicenter study.
Polat H., Çoban E., Çerme E., Kahveci G. B., Geçgel A., Dama P. E., et al.
Annals of Saudi medicine
, vol.45, no.4, pp.249-255, 2025 (SCI-Expanded, Scopus)
2025
202529. Clinicopathological Features and Survival Outcomes of Colorectal Cancer Patients Under 40 Years: A 20-Years Single-Center Experience
Kaan A., Demircan N. C., ÖZGÜR S. Ş., AKYOL T. B., majıdova n., Kocaaslan E., et al.
Uluslararası Hematoloji-Onkoloji Dergisi
, vol.35, no.2, pp.104-111, 2025 (SCI-Expanded, Scopus, TRDizin)
2025
202530. Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
Hacioglu M. B., Kucukarda A., Gokmen I., Gurbuz A. F., Araz M., Kahvecioglu F. A., et al.
Prostate
, vol.85, no.7, pp.693-702, 2025 (SCI-Expanded, Scopus)
2025
202531. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)
majıdova n., Yaslikaya S., Mildanoğlu M., Coşkun A., Uzundal D. E., Sahin T. K., et al.
Turkish Journal of Gastroenterology
, vol.36, no.5, pp.293-301, 2025 (SCI-Expanded, Scopus, TRDizin)
2025
202532. Evaluation of Pancreatic Atrophy in Patients with Hepatocellular Carcinoma Receiving Sorafenib Treatment
Kaan A., Zengin G., majıdova n., SEVER N., Ergelen R., Köstek O., et al.
Eurasian Journal of Medical Investigation
, vol.9, no.1, pp.29-35, 2025 (TRDizin)
2025
202533. Darolutamide: A New Hope in the Battle Against Prostate Cancer Plain Summary
Sari M., Köstek O.
Eurasian Journal of Medical Investigation
, vol.9, no.1, pp.1-11, 2025 (TRDizin)
2025
202534. Efficacy of Combined Bevacizumab and Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Type 1 Receptor Blockers in Metastatic Colorectal Cancer Patients
Güren A. K., Majidova N., Çakır İ., Sever N., Kocaaslan E., Erel P., et al.
Middle East Journal of Cancer
, vol.16, no.2, pp.162-169, 2025 (ESCI, Scopus)
2025
202535. Effects of neoadjuvant and adjuvant chemotherapy on survival in muscle-invasive bladder cancer: A multicenter study
majıdova n., Öztürk A. E., Çolak R., yalıcı ö., İÇLİ M. C., KÖKSAL B., et al.
Turkish Journal of Clinics and Laboratory
, vol.16, no.1, pp.123-130, 2025 (TRDizin)
2025
202536. Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
SEVER N., ŞİMŞEK F., Onur İ. D., Arvas H., GULIYEV T., Şakalar T., et al.
Journal of Clinical Medicine
, vol.14, no.6, 2025 (SCI-Expanded, Scopus)
2025
202537. Sex-related disparities in outcomes of survival in biliary tract cancer patients.
Sever N., Yunusov E., Majidova N., Kocaaslan E., Erel P., Ağyol Y., et al.
Journal of cancer research and clinical oncology
, vol.151, no.2, pp.95, 2025 (SCI-Expanded, Scopus)
2025
202538. Evaluation of Dose Reduction Factors and Impact on Progression-Free Survival in Patients Treated with CDK 4/6 Inhibitors
Güren A. K., Guliyev M., Alan Ö., Çadırci K., Belevi İ. N., Gültürk İ., et al.
Journal of Clinical Medicine
, vol.14, no.4, 2025 (SCI-Expanded, Scopus)
2025
202539. Assessing the Efficacy and Safety of Shorter versus Extended Adjuvant Treatment Duration for Stage III Low-Risk Colon Cancer: A Comparative Analysis.
Kalkan N., Ucar G., Esen S., Bardakci M., AYDIN S., Celebi A., et al.
Nigerian journal of clinical practice
, vol.28, no.2, pp.212-218, 2025 (SCI-Expanded, Scopus)
2025
202540. Oncological perspective on Kaposi sarcoma: A single-centre experience
Guren A. K., Cakir I., Majidova N., Sever N., Kocaaslan E., Erel P., et al.
Marmara Medical Journal
, vol.38, no.1, pp.9-14, 2025 (ESCI, Scopus, TRDizin)
2025
202541. Impact of renin angiotensin system inhibitors on survival of patients with metastatic non-small cell lung cancer
Sever N., Yunusov E., Çelebi A., Yaşar A., Majidova N., Kocaaslan E., et al.
Annals of Saudi Medicine
, vol.45, no.1, pp.18-24, 2025 (SCI-Expanded, Scopus)
2025
202542. Sorafenib vs chemotherapy in the treatment of locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: real-world data from Turkey
Majidova N., Aghamaliyeva S., Guliyev M., Dinc G., Akyıldız A., Ozcan E., et al.
Journal of Chemotherapy
, vol.37, no.8, pp.735-740, 2025 (SCI-Expanded, Scopus)
2025
202543. The Effect of PET/CT SUV max Value on Anti-EGFR Treatment Response in Lung Adenocarcinoma
Ercelep O., Isik S., ERCAN E., KÖSTEK O., Bayoglu V., Celebi A., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
, vol.35, no.3, pp.159-165, 2025 (SCI-Expanded, Scopus)
2025
202544. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis
SEVER N., Yıldırım S., Gurbuz A. F., Karakaş Kılıç D., Zeynelgil E., Altintaş Y. E., et al.
Medicina (Lithuania)
, vol.61, no.1, 2025 (SCI-Expanded, Scopus)
2025
202545. Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups
Ozcan E., Gokmen I., Akgul F., Kahvecioglu F. A., Celebi A., KÖSTEK O., et al.
Breast Journal
, vol.2025, no.1, 2025 (SCI-Expanded, Scopus)
2025
202546. Assessment of new pathological markers in early stage colon cancer: Insights and limitations
ERDOĞAN B., Keskin F. E. U., Özcan E., Küçükarda A., Güren A. K., KÖSTEK O., et al.
World Journal of Gastrointestinal Oncology
, vol.17, no.3, 2025 (SCI-Expanded, Scopus)
2025
202547. Impact of Sarcopenia and Osteopenia on Prognosis in Metastatic Biliary Tract Cancer: A Single Center Experience.
Sever N., Yunusov E., Çağlar E. İ., Çelebi A., Majidova N., Kocaaslan E., et al.
Nutrition and cancer
, vol.77, no.6, pp.610-618, 2025 (SCI-Expanded, Scopus)
2024
202448. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.
Scientific Reports
, vol.14, no.1, 2024 (SCI-Expanded, Scopus)
2024
202449. Which factors help to determine the long-term response to first-line tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: A Turkish multicenter study
Majidova N., Seyyar M., Bayraktar D. I., Dinç G., İsgandarov E., Huseynov J., et al.
Biomolecules and Biomedicine
, vol.24, no.6, pp.1776-1784, 2024 (SCI-Expanded, Scopus)
2024
202450. Efficacy of Systemic Treatments in Patients With Metastatic Lung Invasive Mucinous Adenocarcinoma
Demir T., Araz M., Moloney C., Hendem E., Koçak M. Z., ERMAN M., et al.
Clinical Lung Cancer
, vol.25, no.7, 2024 (SCI-Expanded, Scopus)
2024
202451. The Prognostic Importance of Clinicopathological Factors in Patients with Osteosarcoma Who Received Neoadjuvant Therapy; A Single Center Experience
Simsek F., majıdova n., Kircali M. F., SEVER N., çelebi a., ARIKAN R., et al.
Eurasian Journal of Medical Investigation
, vol.8, no.3, pp.184-192, 2024 (TRDizin)
2024
202452. Evaluating the Role of Nrf-2/HO-1 Pathway in Glioblastoma Treatment Efficacy: A Co-Culture Study
Güneş Z., Başkent M. F., Arslan S., Atasoy B. M., Köstek O., Şahin A., et al.
CLINICAL AND EXPERIMENTAL HEALTH SCIENCES
, vol.14, no.3, pp.760-767, 2024 (ESCI, TRDizin)
2024
202453. HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: A case report
Güren A. K., KOCAASLAN E., AĞYOL Y., Majidova N., Sever N., EREL P., et al.
Anti-Cancer Drugs
, vol.35, no.8, pp.769-773, 2024 (SCI-Expanded, Scopus)
2024
202454. Clinicopathologic Features and Efficacy of Induction Chemotherapy in Nasopharyngeal Carcinoma: Real-World Experience
Majidova N., SARI M., Kahvecioglu F. A., Ozcan E., Akdag M. O., Dogan A., et al.
Oncology Research and Treatment
, vol.47, no.7-8, pp.360-367, 2024 (SCI-Expanded, Scopus)
2024
202455. Gastrointestinal Metastases From Lobular Breast Carcinoma: A Literature Review.
Kioleoglou Z., Georgaki E., Koufopoulos N., Kostek O., Volakakis N., Dimitriadou A., et al.
Cureus
, vol.16, no.7, 2024 (ESCI)
2024
202456. Evaluating therapeutic efficacy of extended shelf-life90Y glass microspheres in transarterial radioembolization for colorectal cancer: a quantitative FDG PET/CT analysis
KESİM S., Balaban Genc Z. C., SOYDEMİR E., BALTACIOĞLU F., Kissa T. N., ÖZDEMİR B., et al.
Nuclear Medicine Communications
, vol.45, no.4, pp.268-277, 2024 (SCI-Expanded, Scopus)
2024
202457. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy
Ilhan Y., Ucar G., Baser M. N., Guzel H. G., Efil S. C., Demir B., et al.
Expert Opinion on Pharmacotherapy
, vol.25, no.11, pp.1555-1563, 2024 (SCI-Expanded, Scopus)
2024
202458. Systemic Inflammation Response Index and Pan-Immune-Inflammation Value: Prognostic Significance in Metastatic Melanoma
Majidova N., Kircali M. F., Güren A. K., Sever N., KOCAASLAN E., AĞYOL Y., et al.
Journal of Oncological Science
, vol.10, no.3, pp.144-149, 2024 (Scopus, TRDizin)
2024
202459. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing
KÖSTEK O., DEMİREL A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.
Journal of Chemotherapy
, vol.36, no.7, pp.613-621, 2024 (SCI-Expanded, Scopus)
2024
202460. Long-Term Survival and Disease-Free Rates in Locoregional Anal Squamous Cell Carcinoma: An Institutional Experience
Sever N., Yildirim S., Yildiz H. S., Dinc Sonusen S., Celebi A., Majidova N., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
, vol.34, no.4, pp.213-219, 2024 (SCI-Expanded, Scopus, TRDizin)
2024
202461. Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience
Majidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
, vol.34, no.1, pp.20-27, 2024 (SCI-Expanded, Scopus, TRDizin)
2023
202362. Evaluation of Clinicopathological Characteristics and Survival Outcomes of Young Gastric Cancer Patients, Single Center Experience
ARIKAN R., Telli T. A., ışık s., Sari M., Köstek O., Ercelep Ö., et al.
Eurasian Journal of Medical Investigation
, vol.7, no.3, pp.296-302, 2023 (TRDizin)
2023
202363. SEASONAL VARIATION OF VITAMIN-D LEVELS IN THE ADULT POPULATION IN ISTANBUL/TURKEY: A POPULATION-BASED STUDY
Eken E., UZUNLULU M., Köstek O., ISMAN F. K., Oguz A.
Sabiad
, vol.6, no.3, pp.270-275, 2023 (TRDizin)
2023
202364. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score
BAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., et al.
Journal of Clinical Medicine
, vol.12, no.19, 2023 (SCI-Expanded, Scopus)
2023
202365. Major and minor salivary gland cancers: A multicenter retrospective study
Hacioglu M. B., ERDOĞAN B., Bardakcı M., Algın E., Gulbagcı B., Hacibekiroglu I., et al.
Head and Neck
, vol.45, no.7, pp.1643-1653, 2023 (SCI-Expanded, Scopus)
2023
202366. Prognostic significance of mucinous histology in left‑sided metastatic colorectal cancers with wild‑type RAS and evaluation of backbone chemotherapy regimens
Arikan R., Atci M. M., Ay S., Ayhan M., Demircan N. C., Telli T. A., et al.
Oncology Letters
, vol.25, no.5, 2023 (SCI-Expanded, Scopus)
2023
202367. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.
Arikan R., Ozguven S., Telli T. A., Isik S., Demircan N. C., Basoglu T., et al.
Acta radiologica (Stockholm, Sweden : 1987)
, vol.64, no.5, pp.2040-2049, 2023 (SCI-Expanded, Scopus)
2023
202368. Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib.
Erdogan B., Ozcan E., Gokmen I., Gokyer A., Kucukarda A., Kostek O., et al.
Journal of cancer research and therapeutics
, vol.19, no.3, pp.762-767, 2023 (SCI-Expanded, Scopus)
2023
202369. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib
ARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., et al.
Journal of Oncological Science
, vol.9, no.2, pp.53-61, 2023 (Scopus, TRDizin)
2022
202270. BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers
Osman K., Ahmet K., Hilmi T., Ilker N., Ercan O., Devrim C., et al.
Balkan Journal of Medical Genetics
, vol.25, no.2, pp.5-14, 2022 (SCI-Expanded, Scopus)
2022
202271. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy
AKIN TELLİ T., ÖZTÜRK M. S., Alan O., Hasanov R., KÖSTEK O., Arikan R., et al.
FUTURE ONCOLOGY
, vol.18, pp.2425-2439, 2022 (SCI-Expanded, Scopus)
2022
202272. Predictive value of (18)F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy.
Başoğlu T., Özgüven S., Özkan H. Ş., Çınar M., Köstek O., Demircan N. C., et al.
Revista espanola de medicina nuclear e imagen molecular
, vol.41, no.3, pp.171-178, 2022 (SCI-Expanded)
2022
202273. Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy Valor predictivo de los índices 18F-FDG PET/TC sobre la carga tumoral residual en pacientes con cáncer de mama extenso tratadas con quimioterapia neoadyuvante
Başoğlu T., ÖZGÜVEN S., ŞAHİN ÖZKAN H., Çınar M., Köstek O., Can Demircan N., et al.
Revista Espanola de Medicina Nuclear e Imagen Molecular
, vol.41, pp.171-178, 2022 (SCI-Expanded, Scopus)
2022
202274. The Relationship between Nutritional Parameters and Thrombosis Risk in Cancer Patients
Sari M., İLHAN Y., SEZGİN GÖKSU S., Kostek O., TATLI A. M., Coskun H. S.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
, vol.74, no.4, pp.1370-1375, 2022 (SCI-Expanded, Scopus)
2022
202275. Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma
Gokyer A., Kucukarda A., Kostek O., Gokmen I., Ozcan E., Sayin S., et al.
TUMORI JOURNAL
, vol.108, no.2, pp.141-146, 2022 (SCI-Expanded, Scopus)
2022
202276. Prognostic Factors for Survival in Transverse Colon Cancers
Kucukarda A., Gokyer A., Sayin S., Gokmen I., Ozcan E., Kostek O., et al.
JOURNAL OF GASTROINTESTINAL CANCER
, vol.53, no.1, pp.31-40, 2022 (ESCI, Scopus)
2022
202277. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
AYHAN M., ABAMOR E., Coban Kokten S., ODABAŞ H., TATAROĞLU ÖZYÜKSELER D., KÖSTEK O., et al.
Eurasian Journal of Medical Investigation
, vol.6, pp.165-175, 2022 (TRDizin)
2022
202278. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Aktürk Esen S., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al.
Bosnian journal of basic medical sciences
, vol.22, pp.818-825, 2022 (SCI-Expanded, Scopus)
2022
202279. Varicella-Zoster Virus Infection and Brivudine Therapy: Unexpected Response in Sarcoma Patient
KÖSTEK O., Sari M., BAYOĞLU İ. V.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, vol.6, no.2, pp.182-185, 2022 (ESCI, TRDizin)
2022
202280. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma
AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., et al.
Nutrition and Cancer
, vol.74, no.7, pp.2499-2507, 2022 (SCI-Expanded, Scopus)
2021
202181. Breast, ovarian and other site cancer patients with BRCA 1/2 mutations: Data from Turkish multicenter retrospective study
KÖSTEK O., KÜÇÜKARDA A., Tozkir H., Nihat Okten I., Ozden E., ÇABUK D., et al.
Journal of B.U.ON.
, vol.26, no.6, pp.2654-2661, 2021 (SCI-Expanded, Scopus)
2021
202182. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience
Ayhan M., Odabas H., Turan N., Ozyukseler D. T., Kostek O., Alkan G., et al.
JOURNAL OF CHEMOTHERAPY
, vol.33, no.7, pp.499-508, 2021 (SCI-Expanded, Scopus)
2021
202183. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?
Erdogan B., Kostek O., Bekir Hacioglu M., Gokyer A., Kucukarda A., Ozcan E., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.26, no.5, pp.2196-2201, 2021 (SCI-Expanded, Scopus)
2021
202184. The association between post-progression survival and clinical characteristics of patients with metastatic colon cancer: A single center experience.
Engin Ozekin M., Gokyer A., Kucukarda A., Kostek O., Issever K., Erdogan B.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.26, no.5, pp.1887-1892, 2021 (SCI-Expanded, Scopus)
2021
202185. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D., Olmez O. F., Sumbul A. T., ARTAÇ M., Ozhan N., Akar E., et al.
European urology focus
, vol.7, no.5, pp.1061-1066, 2021 (SCI-Expanded, Scopus)
2021
202186. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., et al.
CANCER INVESTIGATION
, vol.39, no.6-7, pp.473-481, 2021 (SCI-Expanded, Scopus)
2021
202187. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al.
International journal of clinical oncology
, vol.26, no.8, pp.1506-1513, 2021 (SCI-Expanded, Scopus)
2021
202188. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A., Sayın S., Gokyer A., Kucukarda A., Kostek O., Bekir Hacıoglu M., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.26, no.4, pp.1628-1634, 2021 (SCI-Expanded, Scopus)
2021
202189. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?
Ayhan M., Turan N., Kostek O., Tufan G., Ozyukseler D. T., Odabas H., et al.
CURRENT PROBLEMS IN CANCER
, vol.45, no.3, 2021 (SCI-Expanded, Scopus)
2021
202190. Author`s Reply.
Keskinler M. V., Köstek O., Erok B., Telci Ö., Danacıoğlu O., Oğuz A.
Anatolian journal of cardiology
, vol.25, no.6, pp.458-459, 2021 (SCI-Expanded, Scopus, TRDizin)
2021
202191. The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.
Gokyer A., Kucukarda A., Kostek O., Sayin S., Can N., Hacıoglu B., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.26, no.3, pp.1034-1039, 2021 (SCI-Expanded, Scopus)
2021
202192. Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival.
Kucukarda A., Gokyer A., Gokmen I., Bekir Hacioglu M., Kostek O., Kurt N., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.26, no.3, pp.853-860, 2021 (SCI-Expanded, Scopus)
2021
202193. Perioperative myocardial damage and the incidence of type 2 myocardial infarction in patients with intermediate and high cardiovascular risk
Keskinler M. V., Kostek O., Erok B., Telci O., Danacioglu O., OĞUZ A.
ANATOLIAN JOURNAL OF CARDIOLOGY
, vol.25, no.2, pp.89-95, 2021 (SCI-Expanded, Scopus, TRDizin)
2021
202194. Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.
Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.
JOURNAL OF CLINICAL ONCOLOGY
, vol.39, no.6, 2021 (SCI-Expanded, Scopus)
2021
202195. Is lymph node dissection necessary for staging while undergoing nephrectomy in patients with renal cell carcinoma?
Demir T., Aliyev A., BEŞİROĞLU M., Araz M., Kostek O., Sakin A., et al.
CURRENT PROBLEMS IN CANCER
, vol.45, no.1, 2021 (SCI-Expanded, Scopus)
2021
202196. Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer.
Hacibekiroglu I., Ozkul O., Cakir E., Kostek O., Karatas F., Esenkaya A., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.26, no.1, pp.79-86, 2021 (SCI-Expanded, Scopus)
2021
202197. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (>= 75) patients
Alkan A., GÜÇ Z. G., Gurbuz M., ozgun G., Degirmencioglu S., Dogan M., et al.
JOURNAL OF MENS HEALTH
, vol.17, pp.128-134, 2021 (SCI-Expanded, Scopus)
2020
202098. Prognostic Effect of Albumin-Bilirubin Grade on Survival in Advance Gastric Cancer Patients with de-novo Liver Metastasis
Küçükarda A., Gökyer A., Gökmen İ., Köstek O., Hacioglu B., UZUNOGLU S., et al.
Journal of oncological sciences
, vol.6, no.3, pp.133-140, 2020 (Scopus, TRDizin)
2020
202099. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer
Kostek O.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, vol.43, no.12, pp.905, 2020 (SCI-Expanded, Scopus)
2020
2020100. Introduction of a novel quantitative scoring system for acanthosis nigricans and its validation in a pilot study
Karadag A. S., Uzuncakmak T. K., Ozlu E., Takir M., Karadag R., Kostek O., et al.
DERMATOLOGIC THERAPY
, vol.33, no.6, 2020 (SCI-Expanded, Scopus)
2020
2020101. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study
Gokyer A., Kucukarda A., Kostek O., Hacioglu M. B., UZUNOĞLU S., Kula O., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, vol.25, no.10, pp.1757-1762, 2020 (SCI-Expanded, Scopus)
2020
2020102. Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
Ucar G., Acikgoz Y., Ergun Y., Bal O., Yilmaz M., Karakaya S., et al.
CUREUS
, vol.12, no.9, 2020 (ESCI)
2020
2020103. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.25, no.4, pp.1897-1903, 2020 (SCI-Expanded, Scopus)
2020
2020104. The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas
Korkmaz U., Hacioglu M. B., Kostek O., SÜT N., Kodaz H., ERDOĞAN B., et al.
POLISH JOURNAL OF RADIOLOGY
, vol.85, 2020 (ESCI, Scopus)
2020
2020105. Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?
Bozkaya Y., Kostek O., Sakin A., Ozyukseler D. T., Sakalar T., Cil I.
SUPPORTIVE CARE IN CANCER
, vol.28, no.5, pp.2273-2282, 2020 (SCI-Expanded, Scopus)
2020
2020106. Sarcopenia and Inflammation with Immunotherapy
Kostek O., Demir T.
ONCOLOGIST
, vol.25, no.5, 2020 (SCI-Expanded, Scopus)
2020
2020107. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience.
Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.
Journal of oncological sciences , vol.38, no.6_suppl, pp.1-5, 2020 (SCI-Expanded, TRDizin)
2020
2020108. Does celiac disease impair coronary microvascular circulation: Coronary flow velocity reserve of patients with celiac disease
Caliskan Z., TELCİ ÇAKLILI Ö., Kahraman R., Ozcan F. B., Sayar S., Kostek O., et al.
ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES
, vol.37, no.1, pp.34-40, 2020 (SCI-Expanded, Scopus)
2020
2020109. T helper 1 cytokines and their relationship with beta cell function in type 1 diabetes T helper 1 sitokinleri ve tip 1 diyabette beta hücre fonksiyonu ile ilişkileri
Tamer G., İşbilen Başok B., Doğan B., Telci Çaklili Ö., KÖSTEK O.
Turkish Journal of Endocrinology and Metabolism
, vol.24, no.3, pp.177-183, 2020 (ESCI, Scopus, TRDizin)
2020
2020110. C-Reactive Protein to Albumin Ratio is an Indicator of Poor Prognosis for Patients with Biliary Tract Cancer
Demir T., KÖSTEK O., Araz M., Sakin A., Aliyev A., Besiroglu M., et al.
Eurasian Journal of Medicine and Oncology
, vol.4, no.1, pp.65-70, 2020 (ESCI, Scopus, TRDizin)
2020
2020111. Comparison of neoadjuvant chemotherapy and bladder-preserving chemoradiation in patients with non-metastatic, muscle-invasive bladder cancer: A single-center experience
Gökyer A., KÜÇÜKARDA A., KÖSTEK O., HACIOĞLU M. B., İşsever K., Özler T., et al.
Journal of Oncological Science
, vol.6, no.3, pp.141-146, 2020 (Scopus, TRDizin)
2019
2019112. The albumin-bilirubin (ALBI) grade as a significant prognostic factor in colorectal cancer patients with liver metastases
DEMİRCAN N. C., KÖSTEK O., GÖKYER A., KÜÇÜKARDA A., HACIOĞLU M. B., ERDOĞAN B., et al.
Journal of Surgery and Medicine , 2019 (Peer-Reviewed Journal)
2019
2019113. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib
Gokyer A., Kucukarda A., Kostek O., Hacioglu M. B., Sunal B. S., Demircan N. C., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY
, vol.21, no.11, pp.1518-1523, 2019 (SCI-Expanded, Scopus)
2019
2019114. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer
Kostek O., Demircan N. C., Gokyer A., Kucukarda A., Sunal B. S., Hacioglu M. B., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY
, vol.21, no.11, pp.1510-1517, 2019 (SCI-Expanded, Scopus)
2019
2019115. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102.
Bekir Hacioglu M., Kostek O., Kurt N., Kucukarda A., Gokyer A., Ustabasioglu F. E., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, vol.24, no.5, pp.2198-2204, 2019 (SCI-Expanded, Scopus)
2019
2019116. Clinical characteristics and overdose risk factors of patients hospitalized due to warfarin overdose
ORAL A., BAŞÇI S., KÖSTEK O., UZUNLULU M.
Demiroğlu Bilim Üniversitesi Florence Nightingale Tıp Dergisi , vol.5, no.2, pp.63-71, 2019 (TRDizin)
2019
2019117. Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer?
Kostek O., Bozkaya Y., Hacioglu M. B., Ozdemir N. Y., Yilmaz E., Demircan N. C., et al.
ARCHIVES OF IRANIAN MEDICINE
, vol.22, no.5, pp.236-241, 2019 (SCI-Expanded, Scopus)
2019
2019118. Effect of low-dose acitretin treatment on pituitary hormones in psoriasis vulgaris: A retrospective study
Karadag A. S., Ozlu E., Kostek O., Bilgili S. G., Balaharoglu R., Ertugrul D. T.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
, vol.85, no.3, pp.300-304, 2019 (SCI-Expanded, Scopus)
2019
2019119. CLINICAL FEATURES AND FOLLOW-UP OF PURE SEMINOMA CASES: SINGLE CENTER EXPERIENCE
Gökyer A., KÜÇÜKARDA A., Köstek O.
Namık Kemal Tıp Dergisi
, vol.7, no.2, pp.128-132, 2019 (TRDizin)
2019
2019120. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer
Kostek O., Yilmaz E., Hacioglu M. B., Demircan N. C., Gokyer A., UZUNOĞLU S., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, vol.83, no.4, pp.735-742, 2019 (SCI-Expanded, Scopus)
2019
2019121. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients
Bozkaya Y., Erdem G. U., Demirci N. S., Yazic O., Ozdemir N. Y., Kostek O., et al.
CURRENT MEDICAL RESEARCH AND OPINION
, vol.35, no.2, pp.275-282, 2019 (SCI-Expanded, Scopus)
2019
2019122. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Kostek O., Hacioglu M. B., Sakin A., Demir T., Sari M., Ozkul O., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, vol.83, no.1, pp.115-122, 2019 (SCI-Expanded, Scopus)
2019
2019123. Effect of somatostatin analogs on prostate volume Somatostatin analoglarinin prostat volümü üzerine etkisi
Kostek O., Hacioglu M. B.
Medeniyet Medical Journal
, vol.34, no.2, pp.176-181, 2019 (Scopus, TRDizin)
2019
2019124. Assessment of Duodenal Diverticula: Computed Tomography Findings
Yilmaz E., Kostek O., Hereklioglu S., Goktas M., TUNÇBİLEK N.
CURRENT MEDICAL IMAGING
, vol.15, no.10, pp.948-955, 2019 (SCI-Expanded, Scopus)
2019
2019125. The impact of prognostic nutritional index on coronary flow reserve in patients with inflammatory bowel disease İnflamatuvar bağırsak hastalarında prognostik nütrisyonel indeksin koroner akım rezervi üzerine etkisi
Caliskan Z., Tatlisu M. A., Kahraman R., Gokturk S., Sayar S., Kostek O., et al.
Medeniyet Medical Journal
, vol.34, no.3, pp.271-277, 2019 (Scopus, TRDizin)
2019
2019126. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes
Esin E., Oksuzoglu B., Bilici A., Cicin I., Kostek O., Kaplan M. A., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, vol.83, no.1, pp.131-143, 2019 (SCI-Expanded, Scopus)
2019
2019127. Lipid profile, atherogenic indices, and their relationship with epicardial fat thickness and carotid intima-media thickness in celiac disease
Caliskan Z., Demircioglu K., Sayar S., Kahraman R., TELCİ ÇAKLILI Ö., Ozcan F. B., et al.
NORTHERN CLINICS OF ISTANBUL
, vol.6, no.3, pp.242-247, 2019 (ESCI, TRDizin)
2018
2018128. Investigation of prevalence of insulin resistance and metabolic syndrome in patients with gastric and colon carcinoma
Çelik M., AKYER E., YORULMAZ E., ÇİFTÇİ H., ÇAKICI V., KÖSTEK O.
Eurasian Journal of Medical Investigation , vol.2, no.3, pp.168-171, 2018 (Peer-Reviewed Journal)
2018
2018129. A retrospective study on potential drug interactions: A single center experience
Korucu F. C., Senyigit E., KÖSTEK O., Demircan N. C., Erdogan B., Uzunoglu S., et al.
Journal of Oncological Sciences , vol.4, no.2, pp.80-84, 2018 (Peer-Reviewed Journal)
2018
2018130. Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma
Kostek O., Yilmaz E., Hacioglu M. B., ERDOĞAN B., Kodaz H., Bekmez E. T., et al.
JOURNAL OF BUON
, vol.23, no.4, pp.979-984, 2018 (SCI-Expanded, Scopus)
2018
2018131. BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey
CAN N., TAŞTEKİN E., Deniz Yalta T., SÜT N., KORKMAZ S., USTA U., et al.
TURKISH JOURNAL OF PATHOLOGY
, vol.34, no.2, pp.134-142, 2018 (ESCI, Scopus, TRDizin)
2018
2018132. Enzalutamide in Prostate Cancer, A Review on Enzalutamide and cancer
ERDOĞAN B., KÖSTEK O., HACIOĞLU M. B.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, vol.2, no.3, pp.121-129, 2018 (Peer-Reviewed Journal)
2018
2018133. Clinical predictive factors associated with pathologic complete response in locally advanced rectal cancer
Bozkaya Y., Özdemir N. Y., Erdem G. U., Güner E. K., Ürün Y., Demirci N. S., et al.
Journal of Oncological Sciences , vol.4, no.1, pp.5-10, 2018 (Peer-Reviewed Journal)
2018
2018134. Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome
Kanbay A., Ceylan E., Koseoglu H. I., ÇALIŞKAN M., Takir M., Tulu S., et al.
CLINICAL RESPIRATORY JOURNAL
, vol.12, no.1, pp.84-90, 2018 (SCI-Expanded, Scopus)
2018
2018135. Assessment of cardiovascular findings in FMF related amyloid patients Ailevi akdeniz ateşine ikincil gelişen amiloidozda kardiyovasküler bulguların değerlendirilmesi
Köstek O., Takir M., Çalişkan M., Oğuz A.
Medeniyet Medical Journal
, vol.33, no.3, pp.149-157, 2018 (Scopus, TRDizin)
2018
2018136. Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?
Bozkaya Y., Ozdemir N. Y., Sezer S., Kostek O., Demirci N. S., Yazici O., et al.
CANCER BIOMARKERS
, vol.22, no.1, pp.143-149, 2018 (SCI-Expanded, Scopus)
2017
2017137. Effects of Low Intensity Exercise Against Apoptosis and Oxidative Stress in Streptozotocin-induced Diabetic Rat Heart
Kanter M., Aksu F., Takir M., Kostek O., Kanter B., Oymagil A.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
, vol.125, no.9, pp.583-591, 2017 (SCI-Expanded, Scopus)
2017
2017138. Cardiac invasion of HCC: Clinical image
KÖSTEK O., karakaya tosun i., Tecimen H., Kodal N. S.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, vol.1, no.4, pp.243, 2017 (Peer-Reviewed Journal)
2017
2017139. Assessment of prognostic factors in epithelial ovarian cancer
ÖNAL Y., KÖSTEK O., HACIOĞLU M. B., ERDOĞAN B., KODAZ H., TÜRKMEN BEKMEZ E., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, vol.1, no.2, pp.61-68, 2017 (Peer-Reviewed Journal)
2017
2017140. A Rare Cause of Acute Kidney Injury: Renal ArterialThrombosis in a Small Cell Lung Cancer Patient
KÖSTEK O., HACIOĞLU M. B., ORMAN S., ÇETİN C., KODAL N. S., ERDOĞAN B., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, vol.1, no.1, pp.41-43, 2017 (Peer-Reviewed Journal)
2017
2017141. Metastasis of Transitional Cell Carcinoma of the Bladder to the Orbit: A Case Report
GENÇ A. C., HACIOĞLU M. B., KÖSTEK O., HACIBEKİROĞLU İ.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, vol.1, no.1, pp.47-48, 2017 (Peer-Reviewed Journal)
2017
2017142. The effect of CPAP therapy on insulin-like growth factor and cognitive functions in obstructive sleep apnea patients
Kanbay A., Demir N. C., TUTAR N., Kostek O., Simsek Z. O., Buyukoglan H., et al.
CLINICAL RESPIRATORY JOURNAL
, vol.11, no.4, pp.506-513, 2017 (SCI-Expanded, Scopus)
2017
2017143. Frequency of RAS Mutations (KRAS, NRAS, HRAS) in Human Solid Cancer
KODAZ H., KÖSTEK O., HACIOĞLU M. B., ERDOĞAN B., KODAZ ELPEN Ç., HACIBEKİROĞLU İ., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, vol.1, no.1, pp.1-7, 2017 (Peer-Reviewed Journal)
2017
2017144. Combination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma: A Case Report
KODAZ H., HACIOĞLU M. B., KÖSTEK O., ERDOĞAN B., TAŞTEKİN E., KODAZ ELPEN Ç., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, vol.1, no.1, pp.38-40, 2017 (Peer-Reviewed Journal)
2017
2017145. Morning blood pressure surge is associated with carotid intima-media thickness in prehypertensive patients
Alpaydin S., Turan Y., ÇALIŞKAN M., Caliskan Z., Aksu F., ÖZYILDIRIM S., et al.
BLOOD PRESSURE MONITORING
, vol.22, no.3, pp.131-136, 2017 (SCI-Expanded, Scopus)
2017
2017146. Chemerin as a marker of subclinical cardiac involvement in psoriatic patients
Aksu F., ÇALIŞKAN M., Keles N., Toprak A. E., Uzuncakmak T. K., Kostek O., et al.
CARDIOLOGY JOURNAL
, vol.24, no.3, pp.276-283, 2017 (SCI-Expanded)
2017
2017147. Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis
Hacioglu B. M., Kostek O., ERDOĞAN B., UZUNOĞLU S., ÇİÇİN İ.
JOURNAL OF BUON
, vol.22, no.3, pp.586-591, 2017 (SCI-Expanded, Scopus)
2017
2017148. Effects of the Clinical and Biochemical Features of Patients with Treatment-Resistant Primary Nephrotic Syndrome on Renal Survival
Bilgin S., Ozkok A., Kostek O., Basci S., ÖZKANLI S. Ş., ODABAŞ A. R.
TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
, vol.26, no.1, pp.79-85, 2017 (ESCI, TRDizin)
2017
2017149. K-RAS and N-RAS mutations in testicular germ cell tumors
Hacioglu B. M., Kodaz H., ERDOĞAN B., Cinkaya A., TAŞTEKİN E., Hacibekiroglu I., et al.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
, vol.17, no.2, pp.159-163, 2017 (SCI-Expanded, Scopus)
2017
2017150. Clinical features of the patient with multiple primary tumors: Single center experience
Gokyer A., Kostek O., Hacioglu M. B., ERDOĞAN B., Kodaz H., Turkmen E., et al.
NORTHERN CLINICS OF ISTANBUL
, vol.4, no.1, pp.43-51, 2017 (ESCI, TRDizin)
2017
2017151. Skin findings in autoimmune and nonautoimmune thyroid disease with respect to thyroid functional status and healthy controls
Takir M., Ozlu E., Kostek O., Turkoglu Z., MUTLU H. H., Uzuncakmak T. K., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, vol.47, no.3, pp.764-770, 2017 (SCI-Expanded, Scopus, TRDizin)
2017
2017152. Effects of the Clinical and Biochemical Features of Patients with Treatment-Resistant Primary Nephrotic Syndrome on Renal Survival
BİLGİN S., OZKOK A., Başcı S., Köstek O., Odabas A. R., ÖZKANLI Ş.
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
, vol.26, no.1, pp.79-85, 2017 (Scopus, TRDizin)
2017
2017153. Bone Mineral Density and Osteoporosis in Hyponatremic Versus Normonatremic Patients: A Retrospective 12-Month Analysis
TAKIR M., Bakan A., TAHRA S. T., Köstek O., EREK A., DURAN İ., et al.
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
, vol.26, no.1, pp.29-34, 2017 (TRDizin)
2017
2017154. Bone Mineral Density and Osteoporosis in Hyponatremic Versus Normonatremic Patients: A Retrospective 12-Month Analysis
Takir M., Bakan A., Tahra S. T., Kostek O., Erek A., Duran I., et al.
TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
, vol.26, no.1, pp.29-34, 2017 (ESCI, TRDizin)
2016
2016155. The Influence of On-pump Versus Off-pump Surgery on Short- and Medium-term Postoperative Coronary Flow Reserve After Coronary Artery Bypass Grafting
Ozulku M., Caliskan M., Saba T., Aksu F., Ciftci O., Gullu H., et al.
HEART LUNG AND CIRCULATION
, vol.25, no.12, pp.1232-1239, 2016 (SCI-Expanded, Scopus)
2016
2016156. Cystatin-C and TGF-beta levels in patients with diabetic nephropathy
Takir M., Unal A. D., Kostek O., Bayraktar N., Demirag N. G.
NEFROLOGIA
, vol.36, no.6, pp.653-659, 2016 (SCI-Expanded, Scopus)
2016
2016157. Is activation in inflammatory bowel diseases associated with further impairment of coronary microcirculation?
Caliskan Z., Keles N., Gokturk H. S., Ozdil K., Aksu F., Ozturk O., et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY
, vol.223, pp.176-181, 2016 (SCI-Expanded, Scopus)
2016
2016158. Coronary Flow Velocity Reserve in Burn Injury: A Prospective Clinical Cohort Study
ÇALIŞKAN M., Turk E., Karagulle E., Ciftci O., Oguz H., Kostek O., et al.
JOURNAL OF BURN CARE & RESEARCH
, vol.37, no.5, 2016 (SCI-Expanded, Scopus)
2016
2016159. Durable response with medroxiprogesterone acetate in metastatic renal cell carcinoma: Case report
Hacioglu B. M., KÖSTEK O., ERDOĞAN B., Hilmi K., HACIBEKİROĞLU İ., Turkmen E., et al.
Journal of Oncological Sciences , vol.2, no.2-3, pp.69-70, 2016 (Peer-Reviewed Journal)
2016
2016160. Is the presence of AA amyloidosis associated with impaired coronary flow reserve?
Bulut M., Keles N., Caliskan Z., Kostek O., Aksu F., Ozdil K., et al.
ATHEROSCLEROSIS
, vol.251, pp.389-395, 2016 (SCI-Expanded, Scopus)
2016
2016161. Relationship Between Papillary Thyroid Cancer And Hashimoto’s Disease
Erdoğmuş S., Mümtaz T., KÖSTEK O., Şenol S., Mutlu H. H.
Medeniyet medical journal
, vol.31, no.1, pp.186-191, 2016 (Scopus, TRDizin)
2016
2016162. Is Low Serum Klotho Level Associated with Alterations in Coronary Flow Reserve?
Keles N., ÇALIŞKAN M., Dogan B., Aksu F., Bulur S., Keles N. N., et al.
ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES
, vol.33, no.6, pp.881-888, 2016 (SCI-Expanded, Scopus)
2016
2016163. Association Between Elevated Serum Uric Acid and Vitamin D Insufficiency Among the Middle-Aged and Elderly Population
TAKIR M., SOLAK Y., EREK A., Köstek O., Oral A., ELÇİOĞLU Ö. C., et al.
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
, vol.25, no.2, pp.182-186, 2016 (TRDizin)
2016
2016164. Chronic rhinosinusitis, endothelial dysfunction, and atherosclerosis
ELÇİOĞLU Ö. C., Afsar B., Bakan A., Takir M., Ozkok A., Oral A., et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
, vol.30, no.3, 2016 (SCI-Expanded, Scopus)
2016
2016165. The relation of presenting symptoms with staging, grading, and postoperative 3-year mortality in patients with stage I-III non-metastatic colon cancer
Bedir O., Kiziltas S., Kostek O., ÖZKANLI S. Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY
, vol.27, no.3, pp.239-245, 2016 (SCI-Expanded, Scopus, TRDizin)
2016
2016166. The effects of quercetin on liver regeneration after liver resection in rats
Kanter M., TUNCER İ., Erboga M., Atanassova P., Takir M., Kostek O.
FOLIA MORPHOLOGICA
, vol.75, no.2, pp.179-187, 2016 (SCI-Expanded, Scopus)
2016
2016167. Echocardiographic Epicardial Fat Thickness Measurement and Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus
Nurşen K., Aksu F., Açıksarı G., Demircioğlu K., Yılmaz Y., KÖSTEK O., et al.
Medeniyet medical journal
, vol.31, no.2, pp.115-121, 2016 (Scopus, TRDizin)
2016
2016168. Sistemik AA Amiloidozlu Hastalarda Epikardiyal Yağ DokusuKalınlığı, Benek Takibi Ekokardiyografik Parametreleri veYüksek Duyarlıklı C Reaktif Protein Düzeyleri
keleş n., ÇALIŞKAN M., elçioğlu ö. c., akçakoyun m., bakan a., KÖSTEK O., et al.
MN Kardiyoloji , vol.23, no.1, pp.19-27, 2016 (TRDizin)
2016
2016169. Protective Effects of Curcumin on Intestinal Damage in Cholestatic Rats
Kanter M., Takir M., MUTLU H. H., Kanter B., Kostek O., Toprak A. E.
JOURNAL OF INVESTIGATIVE SURGERY
, vol.29, no.3, pp.128-136, 2016 (SCI-Expanded, Scopus)
2016
2016170. Association Between Elevated Serum Uric Acid and Vitamin D Insufficiency Among the Middle-Aged and Elderly Population
Takir M., Solak Y., Erek A., Kostek O., Oral A., ELÇİOĞLU Ö. C., et al.
TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
, vol.25, no.2, pp.182-186, 2016 (ESCI, TRDizin)
2016
2016171. Is serum Klotho protective against atherosclerosis in patients with type 1 diabetes mellitus?
Keles N., Dogan B., Kalcik M., ÇALIŞKAN M., Keles N. N., Aksu F., et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS
, vol.30, no.1, pp.126-132, 2016 (SCI-Expanded, Scopus)
2016
2016172. An unusual case of peritonitis after vaginal leak in a patient on peritoneal dialysis
Bakan A., Oral A., Kostek O., Ecder S. A., ODABAŞ A. R.
NEFROLOGIA
, vol.36, no.1, pp.85-86, 2016 (SCI-Expanded, Scopus)
2016
2016173. Is triglyceride/HDL ratio a reliable screening test for assessment of atherosclerotic risk in patients with chronic inflammatory disease?
Keles N., Aksu F., Aciksari G., Yilmaz Y., Demircioglu K., Kostek O., et al.
NORTHERN CLINICS OF ISTANBUL
, vol.3, no.1, pp.39-45, 2016 (ESCI, TRDizin)
2016
2016174. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients
Yilmaz I., Ozkok A., Kostek O., Kolukisa A., Duran I., ODABAŞ A. R., et al.
RENAL FAILURE
, vol.38, no.1, pp.89-95, 2016 (SCI-Expanded, Scopus)
2015
2015175. Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia
Takir M., Kostek O., Ozkok A., ELÇİOĞLU Ö. C., Bakan A., Erek A., et al.
JOURNAL OF INVESTIGATIVE MEDICINE
, vol.63, no.8, pp.924-929, 2015 (SCI-Expanded, Scopus)
2015
2015176. Low Serum Level of Klotho Is an Early Predictor of Atherosclerosis
Keles N., ÇALIŞKAN M., Dogan B., Keles N. N., Kalcik M., Aksu F., et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
, vol.237, no.1, pp.17-23, 2015 (SCI-Expanded, Scopus)
2015
2015177. Renalase: Another puzzle piece between hypertension and simple renal cysts?
ELÇİOĞLU Ö. C., Afsar B., Takir M., Toprak A. E., Bakan A., Bakan S., et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY
, vol.47, no.7, pp.1181-1186, 2015 (SCI-Expanded, Scopus)
2015
2015178. The effects of urgent percutaneous coronary intervention on right ventricular systolic functions in non-ST-elevation acute coronary syndromes
Keles N., Kalcik M., ÇALIŞKAN M., Cakir H., Aung S. M., Kostek O., et al.
INTERVENTIONAL MEDICINE AND APPLIED SCIENCE
, vol.7, no.2, pp.69-77, 2015 (ESCI, Scopus)
2015
2015179. Association between asthma self-management knowledge and asthma control in the elderly
Ozturk A. B., Pur L. O., Kostek O., Keskin H.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
, vol.114, no.6, pp.480-484, 2015 (SCI-Expanded, Scopus)
2015
2015180. Varfarin tedavisi alan hastalarda koagülasyon testlerinin terapötik aralıkta olma oranı
Erdemoğlu E., Uzunlulu M., Oğuz A., KÖSTEK O., Telci Ç. Ö.
Medeniyet medical journal
, vol.30, no.3, pp.105-109, 2015 (Scopus, TRDizin)
2015
2015181. Hyperuricemia is associated with progression of IgA nephropathy
Bakan A., Oral A., ELÇİOĞLU Ö. C., Takir M., Kostek O., Ozkok A., et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY
, vol.47, no.4, pp.673-678, 2015 (SCI-Expanded, Scopus)
2015
2015182. The effect of sociodemographic and clinical features on mortality in patients with diagnosis of aspiration pneumonia
Ozer M. N., UZUNLULU M., OĞUZ A., Kostek O., Akyer E., Takir M.
NORTHERN CLINICS OF ISTANBUL
, vol.2, no.1, pp.41-47, 2015 (ESCI, TRDizin)
2015
2015183. Retrobulbar blood flow and carotid intima-media thickness alteration may relate to subclinic atherosclerosis in patients with chronic inflammatory diseases
Keles N., ÇALIŞKAN M., Aksu F. U., Keles N. N., Karagoz V., Tekin A. S., et al.
RENAL FAILURE
, vol.37, no.7, pp.1164-1170, 2015 (SCI-Expanded, Scopus)
2015
2015184. Previous gestational diabetes history is associated with impaired coronary flow reserve
ÇALIŞKAN M., Turan Y., Caliskan Z., Gullu H., Ciftci F. C., Avci E., et al.
ANNALS OF MEDICINE
, vol.47, no.7, pp.615-623, 2015 (SCI-Expanded, Scopus)
2015
2015185. Prognosis of patients in a medical intensive care unit
Unal A. U., Kostek O., Takir M., TELCİ ÇAKLILI Ö., UZUNLULU M., OĞUZ A.
NORTHERN CLINICS OF ISTANBUL
, vol.2, no.3, pp.189-195, 2015 (ESCI, TRDizin)
2014
2014186. Endocan: A New Molecule Playing a Role in the Development of Hypertension and Chronic Kidney Disease?
Afsar B., Takir M., Kostek O., Covic A., Kanbay M.
JOURNAL OF CLINICAL HYPERTENSION
, vol.16, no.12, pp.914-916, 2014 (SCI-Expanded, Scopus)
2014
2014187. Emphysematous pyelonephritis as a cause of diabetic ketoacidosis
KÖSTEK O., TAKIR M., YILMAZ Y., ORAL A.
JSM Clinical Case Reports , vol.2, no.6, pp.1065, 2014 (Peer-Reviewed Journal)
2014
2014188. Zenker’s Diverticulum: Clinical Image
ORAL A., KÖSTEK O., TUNCER İ.
JSM Clinical Case Reports , vol.2, no.5, pp.1056, 2014 (Peer-Reviewed Journal)
2014
2014189. A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators
ÇOLAK Y., Yesil A., MUTLU H. H., Caklili O. T., Ulasoglu C., ŞENATEŞ E., et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES
, vol.23, no.3, pp.311-319, 2014 (SCI-Expanded, Scopus)
2014
2014190. Functioning beta cells in type 1 diabetes may not be as low as it is presumed
Tamer G., Dogan B., Ocakoglu I., Kostek O., Kartal I., Sagun G., et al.
DIABETOLOGIA
, vol.57, 2014 (SCI-Expanded, Scopus)
2014
2014191. Increased morning blood pressure surge and coronary microvascular dysfunction in patient with early stage hypertension
ÇALIŞKAN M., Caliskan Z., Gullu H., Keles N., Bulur S., Turan Y., et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
, vol.8, no.9, pp.652-659, 2014 (SCI-Expanded)
2014
2014192. Leptin Parameters are Associated with Inflammation and Both Anthropometric and Serum Markers of Protein-Energy Wasting in Hemodialysis Patients
Ozkok A., Isbilen B., Erdemoglu E., Ozberk O. M., TELCİ ÇAKLILI Ö., Kostek O., et al.
TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
, vol.23, no.2, pp.85-90, 2014 (ESCI, TRDizin)
2013
2013193. FREQUENCY OF METABOLIC SYNDROME AND NON ALCOHOLIC FATTY LIVER IN BEHCET'S DISEASE
Ulasoglu C., MESCİ B., Karagoz E., Karagoz V., Akin Y., Ozturk H., et al.
NOBEL MEDICUS
, vol.9, no.3, pp.35-42, 2013 (SCI-Expanded, Scopus)
2013
2013194. A rare complication of a rare disease: Amyloidosis in situs inversus
Ozkok A., Keskinler M. V., Eken E., KÖSTEK O., Caklili O., Oral A., et al.
Open Journal of Internal Medicine , vol.3, no.02, pp.55-57, 2013 (Peer-Reviewed Journal)
Papers Presented at Peer-Reviewed Scientific Conferences
2024
20241. HIGH BLOOD PRESSURE THERAPY ADHERENCE AND QUALITY OF LIFE IN CANCER PATIENTS WITH HYPERTENSION
YILMAZ F. N., TEZCAN S., KÖSTEK O.
52nd ESCP Symposium on Clinical Pharmacy. Implementing and scaling sustainable clinical pharmacy practice, Krakow, Poland, 21 - 23 October 2024, (Summary Text)
2023
20232. Alkalen fosfataz yüksekliği ile prezente olan primeri bilinmeyen metastatik adenokarsinom: olgu sunumu
KAVLAK S. Ş., DEMİRTAŞ D., SEVER N., TOPTAŞ T., KÖSTEK O., TAZEGÜL G.
1. Dahiliye Uzmanları Kış Sempozyumu, BAFRA/İSKELE, Cyprus (Kktc), 1 - 03 December 2023, (Summary Text)
2019
20193. Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey
Demirci U., Gokmen E., Eralp Y., Gunduz S., Goksu S. S., KORKMAZ T., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 14 December 2019, vol.80, (Summary Text)
2019
20194. THE ASSOCIATION BETWEEN POST-PROGRESSION SURVIVAL AND CLINICAL CHARACTERISTICS OF THE PATIENTS WITH METASTATIC COLORECTAL CANCER
ÖZEKİN M. E., KÖSTEK O., ERDOĞAN B.
9. INTERNATIONAL GASTROINTESTINAL CANCER CONFERENCE, 6 - 08 December 2019, (Summary Text)
2019
20195. MALİGN MELANOM-HEDEFE YÖNELİK TEDAVİDE TARTIŞMALI KONULAR- 4
KÖSTEK O.
3. MUĞLA MULTİDİSİPLİNER ONKOLOJİK ARAŞTIRMALAR KONGRESİ (AMORE 2019), Muğla, Turkey, 18 - 20 October 2019, pp.58-62, (Full Text)
2019
20196. PAZOPANİBİN TEDAVİ ETKİNLİĞİ DEĞERLENDİRMEDE SİSTEMİK İNFLAMASYON BELİRTEÇLERİ
KÖSTEK O., HACIOĞLU M. B.
KONYA MULTİDİSİPLİNER ONKOLOJİ SEMPOZYUMU, Konya, Turkey, 31 August 2019, (Summary Text)
2019
20197. Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.
IŞIK U., KÖSTEK O., DEMİRAY A. G., DİRİCAN A., ŞİMŞEK M., BÜYÜKŞİMŞEK M., et al.
ASCO 2019, Chicago, United States Of America, 29 May - 02 June 2019, vol.37, pp.16075, (Full Text)
2019
20198. Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçlari- Gerçek Yaşam Verisi
ALKAN A., Güç Z. G., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., et al.
23. Ulusal Kanser Kongresi, Turkey, 17 - 21 April 2019, (Summary Text)
2019
20199. Geriatrik (≥75 Yaş), Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Hastalarında 1. Basamak Anti- Androjen Tedavi Sonuçları- Gerçek Yaşam Verisi
ALKAN A., Güç Z. G., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., et al.
23. Ulusal Kanser Kongresi, Turkey, 17 - 21 April 2019, (Summary Text)
2019
201910. Renal Hücreli Karsinoma Hastalarında Nefrektomi Esnasında Lenf Nodu DiseksiyonuGerekli mi?
DEMİR T., ARAZ M., KÖSTEK O., SAKİN A., SHBAİR A. T., ALİYEV A., et al.
23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019, (Summary Text)
2019
201911. OPERE ERKEN EVRE KÜÇÜK HÜCRELİ DIŞI AKCİĞERKANSERLERİNDE LOKAL/BÖLGESEL YİNELEMEPATERNLERİ
ÖZLER T., SAYNAK M., NURLU D., DEMİR S., KÖSTEK O., KARAMUSTAFAOĞLU Y. A., et al.
23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019, pp.272, (Summary Text)
2019
201912. GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİMETASTATİK PROSTAT KANSERİ (KDMPK)HASTALARINDA 1. BASAMAK ANTİ- ANDROJENTEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ
ALKAN A., SEVGEN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., et al.
23. ULUSAL KANSER KONGRESİ, Antalya, Turkey, 17 - 21 April 2019, pp.300, (Summary Text)
2019
201913. Türkiye’de Yaşa Özgü Akciğer Kanseri İnsidans Oranları:Yaşlılarda Akciğer Kanseri Artmaktadır
SARI M., KÖSTEK O.
Ulusal Akciğer Sağlığı Kongresi 2019, Antalya, Turkey, 13 - 17 March 2019, pp.127-128, (Summary Text)
2018
201814. Karaciğere Metastatik KolorektalKanserde ALBI Skorunun PrognostikÖnemi
DEMİRCAN N. C., KÖSTEK O.
2. Ulusal İmmünoterapi ve Onkoloji Kongresi • 31 Ekim - 4 Kasım 2018, Antalya, Antalya, Turkey, 31 October - 04 November 2018, pp.18, (Summary Text)
2018
201815. Metastatik Kolorektal Kanser Tedavisinde3. Basamak: Yeniden Kemoterapi VsRegorafenib
KÖSTEK O., HACIOĞLU M. B., SAKİN A., DEMİR T., SARI M., ÖZKUL Ö., et al.
2. Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018, (Summary Text)
2018
201816. CHANGES IN LEAN BODY MASS AND SKELETAL MUSCLEAREA DURING PAZOPANIB VS SUNITINIB THERAPY FORMETASTATIC RENAL CANCER
KÖSTEK O., Yılmaz E., DEMİRCAN N. C., GÖKYER A.
2 nd International Congress on Oncological Sciences, Antalya, Turkey, 20 - 23 September 2018, pp.98-99, (Full Text)
2018
201817. METASTATİK KOLOREKTAL KANSERLERDE REGORAFENİB ETKİNLİĞİ SAĞ-SOL FARKI VAR MI?
HACIOĞLU M. B., KÖSTEK O.
TREATMENT MODALITIES FOR STAGE IV DISEASES FOR COLORECTAL CANCER 6 th MEETING, İstanbul, Turkey, 11 - 12 May 2018, (Summary Text)
2018
201818. Can we predict the timing of hepatospecific contrast agent appearance in the bile duct before MRI?
Yılmaz E., KÖSTEK O.
Turkish society of magnetic resonance 23rd annual meeting, Ankara, Turkey, 10 - 12 May 2018, vol.50, pp.137, (Summary Text)
2018
201819. Frequency of malignancy in radiologic imaging in Type 2 DM patients: preliminary findings
Yılmaz E., KÖSTEK O.
7th International Trakya Family Medicine Congress, Edirne, Turkey, 21 - 25 March 2018, pp.122-124, (Full Text)
2018
201820. Malign melanom hastalarında pineal gland kalsifikasyonu sıklık ve prognoz ile ilişkisi
Yılmaz E., KÖSTEK O.
Türk Nöroradyoloji Derneği 27. yıl yıllık toplantısı nöroradyoloji ve baş-boyun radyolojisi, İstanbul, Turkey, 16 - 18 February 2018, pp.24, (Summary Text)
2017
201721. THE EFFECT OF ACITRETIN TREATMENT ON PITUITARY HORMONES IN PSORIASIS VULGARIS: A NONCONTROLLED STUDY
KARADAĞ A. S., ÖZLÜ E., KÖSTEK O., GÜNEŞ BİLGİLİ S., BALAHAROĞLU R., ERTUĞRUL D. T.
2nd International Dermatology and Cosmetology Congress, 15 - 18 March 2017, (Summary Text)
2016
201622. Serum Gas 6 and omentin levels and relationship with flow mediated dilatation, aortic distensibility, left ventricule mass index and disease severity in patients with psoriasis
Toprak A. E., Karadag A. S., ERMAN H., Aksu F., Ustunbas T. K., Kostek O., et al.
41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Turkey, 3 - 08 September 2016, vol.283, pp.111, (Summary Text)
2016
201623. Endocan: A Novel Predictor of Endothelial Dysfunction in Obstructive Sleep Apnea Syndrome
Kanbay A., Ceylan E., ÇALIŞKAN M., Telci O., Kostek O., Erek A., et al.
CHEST World Congress, Shanghai, China, 15 - 17 April 2016, vol.149, (Summary Text)
2015
201524. The effects of serum klotho levels on endothelial function and early atherosclerosis predictors in healty population
Keles N., Caliskan M., Dogan B., Keles N. N., Aksu F., Kostek O., et al.
Congress of the European-Society-of-Cardiology (ESC), London, Canada, 29 August - 02 September 2015, vol.36, pp.581-582, (Summary Text)
2014
201425. Functioning beta cells in type 1 diabetes may not be as low as it is presumed
TAMER H. G., DOĞAN B., OCAKOĞLU İ., KÖSTEK O., İLKAY K., SAĞUN H. G., et al.
50th EASD Annual Meeting, VİYANA, Austria, 15 - 19 September 2014, vol.57, pp.189, (Summary Text)
2014
201426. A Pathophysiological Link: Monocyte Count and LDL CholesterolLevels
TELCİ ÇAKLILI Ö., KÖSTEK O., ÖZTÜRK E., OĞUZ A.
10th INTERNATIONAL CONGRESS OF UPDATE IN CARDIOLOGYAND CARDIOVASCULAR SURGERY, 13 - 16 March 2014, vol.113, pp.14, (Summary Text)
2013
201327. Diabetes mellitus knowledge of nurses
YAVUZ G., OĞUZ A., TELCİ ÇAKLILI Ö., KÖSTEK O.
10th MetabolicSyndrome Symposium, Antalya, Turkey, 5 - 08 September 2013, vol.15, pp.235, (Summary Text)
2013
201328. Does individualized education on diabetes improveglycemic control?
TELCİ ÇAKLILI Ö., ÖZATA M., ARSLAN BAHADIR M., KÖSTEK O., OĞUZ A.
10th MetabolicSyndrome Symposium, Antalya, Turkey, 5 - 08 September 2013, vol.15, pp.241, (Summary Text)
2013
201329. Diabetes risk awareness of general population
FEYİZOĞLU G., DOĞAN B., FEYİZOĞLU H., TELCİ ÇAKLILI Ö., KÖSTEK O., OĞUZ A.
10th MetabolicSyndrome Symposium, Antalya, Turkey, 5 - 08 September 2013, vol.15, pp.235, (Summary Text)
2013
201330. Obesity is the main culprit in polycysticovary syndrome?
KESKİN H., ÇARLIOĞLU A., KARAKILIÇ ULUDAĞ E. Ü., KABİL KUCUR S., GÖZÜKARA İ., KAYA Y., et al.
10th MetabolicSyndrome Symposium, Antalya, Turkey, 5 - 08 September 2013, vol.15, pp.271, (Summary Text)
2013
201331. The Impact of Non-Cardiac Surgery on Electrocardiograph Changes, Troponin Levels in patients with Intermediate and High Risk According to Framingham General Cardiovascular Disease Risk Score
KESKİNLER M. V., Bulur S., Kostek O., Erok B., Can O., Danacioglu Y. O., et al.
29th Turkish Cardiology Congress of the Turkish-Society-of-Cardiology (TSC) with International Participation, Antalya, Turkey, 26 - 29 October 2013, vol.62, (Summary Text)
2013
201332. Association between toll-like receptor 4polymorphism and type 2 diabetes mellitus
MESCİ B., EREN P., KIZILTAŞ Ş., OĞUZ A., TUNCER İ., KÖSTEK O., et al.
15th European Congress of Endocrinology, 27 April - 01 May 2013, vol.32, pp.372, (Summary Text)
2012
201233. Serum and Pleural NTproBNP Levels In Patients with Congestive Heart Failure and Its Contribution to Diagnosis
Arpag H., Kuyucu T., Ordu E. N., Karabay C. Y., OĞUZ A., MESCİ B., et al.
3rd World Heart Failure Congress, İstanbul, Turkey, 29 November - 02 December 2012, vol.30, pp.88, (Summary Text)
2012
201234. Prevalence of abdominal obesity, high bloodpressure and dysglycaemia in hospitalizedpatients
OĞUZ A., MESCİ B., GENCTURK N., ULUS C., ATEŞ M., KÖSTEK O., et al.
9th MetabolicSyndrome Symposium, Antalya, Turkey, 5 - 08 April 2012, vol.13, pp.653, (Summary Text)
2012
201235. Extra foods and drinks of diabetic patients in thehospital
MESCİ B., OĞUZ A., GENCTURK N., ATEŞ M., ULUS C., TELCİ ÇAKLILI Ö., et al.
9th MetabolicSyndrome Symposium, Antalya, Turkey, 5 - 08 April 2012, vol.13, pp.652, (Summary Text)
2012
201236. The problems of oral anticoagulation in patientswith metabolic syndrome, hypertension ordiabetes mellitus
MESCİ B., AGURASLAN E., KARACA M., ZENGİN A., TUSUN E., KÖSTEK O., et al.
9th Metabolic Syndrome Symposium, Antalya, Turkey, 5 - 08 April 2012, vol.13, pp.650, (Summary Text)
2012
201237. Nutritional perception and practice differences indieting
KÖSTEK O., OĞUZ A., MESCİ B., ATEŞ M., GENÇTURK N., TELCİ ÇAKLILI Ö., et al.
9th MetabolicSyndrome Symposium, Antalya, Turkey, 5 - 08 April 2012, vol.13, pp.652, (Summary Text)
2012
201238. Metabolic evaluation of patients with Behcet’sdisease
MESCİ B., OĞUZ A., KAVALA M., İŞBİLEN B., İŞMAN F. K., SADIGOV F., et al.
9th MetabolicSyndrome Symposium, Antalya, Turkey, 5 - 08 April 2012, vol.13, pp.651, (Summary Text)
Books
2024
20241. Advances in Diagnosis and Therapy of Colorectal Carcinoma
Güren A. K., Köstek O.
IntechOpen, London, 2024
2020
20202. Onkolojik Aciller
Köstek O., Hacıoğlu M. B.
Akademisyen Yayınevi Kitabevi, İstanbul, 2020
Funded Projects
2025 - 2026
2025 - 2026Kanda dolaşan tümör hücreleri (CTC) üzerinden genomik profillemeye dayalı kişiselleştirilmiş kanser tedavisinin yönlendirilmesi ve CTC’lerin kültürü ile tedavi etkinliğinin sorgulanması
TUBITAK Project , 1501 - Industry R & D Projects Support Program
Arga K. Y. (Executive), Yılmaz B., Köstek O., Şener Akçora D., Bozkurtlar E.
2022 - 2024
2022 - 2024Kişiselleştirilmiş glioblastoma tedavisi için 3 boyutlu tümör mikroçevrenin oluşturulması ve transkriptom analizi ile belirlenen proteazomal sisteme etkili moleküllerin bu modelde denenmesi
Project Supported by Higher Education Institutions , University Supported Other Projects
(Project Abstract)
Şahin A., Yılmaz B. (Executive), Ünal Yıldırım S., Gündüz O., Arga K. Y., Köstek O., et al.
Activities in Scientific Journals
2025 - Present
2025 - PresentEurasian Journal of Medical Investigation
Editor
Memberships and Roles in Scientific Organizations
2019 - Present
2019 - PresentESMO
Member
2019 - Present
2019 - PresentASCO
Member
2016 - Present
2016 - PresentTTOD
Member